# COSMOS Pharmaceutical vs MatsukiyoCocokara & Co

> Unit: JPY millions (ratios in %)
> Periods: COSMOS Pharmaceutical = FY ending May 2026, consolidated, J-GAAP / MatsukiyoCocokara & Co = FY ending Mar 2026, consolidated, J-GAAP
> Retrieved: 2026-09-30T20:34:25.217Z

| Metric | COSMOS Pharmaceutical | MatsukiyoCocokara & Co |
| --- | ---: | ---: |
| Revenue | 1,099,583 | 1,117,440 |
| Operating income | 42,353 | 84,935 |
| Net income | 32,046 | 55,776 |
| COGS ratio | 79.1% | 64.8% |
| Operating margin | 3.9% | 7.6% |
| Net margin | 2.9% | 5.0% |
| FCF margin | -1.1% | 4.7% |
| Period | FY ending May 2026 | FY ending Mar 2026 |
| Source | S100YYDI | S100YD1I |

## Five-axis industry profile

Each axis shows a rank within that company's primary industry, so peer groups may differ. Missing values are labeled unavailable; no combined score is calculated. Industry rank is not an investment recommendation.

| Axis | COSMOS Pharmaceutical | MatsukiyoCocokara & Co |
| --- | ---: | ---: |
| Revenue growth | 53.1 (16 peers) | 90.6 (16 peers) |
| Profitability | 44.7 (19 peers) | 97.4 (19 peers) |
| Cash conversion | 75 (18 peers) | 30.6 (18 peers) |
| Efficiency | 81.6 (19 peers) | 28.9 (19 peers) |
| Financial strength | — | — |

## Company details

- https://vizora.meequs.com/en/company/cosmos-pharmaceutical/md
- https://vizora.meequs.com/en/company/matsukiyococokara-and-co/md

## Definitions

- Amounts are in millions of JPY (rounded). The period is stated in each table heading
- Operating margin = operating income ÷ revenue. Net income is attributable to owners of the parent when disclosed
- Free cash flow (FCF) = operating cash flow − capital expenditure
- ¥100 model = breakdown per ¥100 of revenue (rounded so parts sum to 100)
- Segment revenues include inter-segment sales and may not sum to consolidated revenue
- Source IDs are EDINET document IDs (docID). "算出" (derived) means computed from other disclosed values
- All figures are extracted mechanically from filings. AI-written text never generates figures
- Source: company filings submitted to EDINET (Financial Services Agency of Japan). Figures were extracted, edited and processed, and charts and text were created, by Vizora — not by the FSA (used under the Public Data License v1.0).